Wegovy And Mounjaro Australia Price Comparison Guide
As GLP-1 weight loss injections become more widely available in Australia, many people are weighing up the costs of Wegovy and Mounjaro. Understanding what you might pay, how PBS eligibility works, and what private clinic pricing looks like can help you make a more informed healthcare decision.
Weight loss injections containing semaglutide and tirzepatide have reshaped how obesity and weight management are approached medically. In Australia, two medications stand out in this space: Wegovy, which contains semaglutide, and Mounjaro, which contains tirzepatide. Both are injectable medications that work on hormonal pathways to reduce appetite and support weight loss, but their availability, pricing structures, and eligibility criteria differ in important ways.
What Are Semaglutide and Tirzepatide?
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management and later approved at higher doses for chronic weight management. Tirzepatide works on both GLP-1 and GIP receptors, making it a dual-action medication. In Australia, Wegovy (semaglutide 2.4mg) has received Therapeutic Goods Administration (TGA) approval for weight management, while Mounjaro (tirzepatide) has been approved for type 2 diabetes and, more recently, gained traction in obesity treatment through private prescriptions.
PBS Access and Prescription Eligibility
One of the most significant cost factors is whether a medication is subsidised under the Pharmaceutical Benefits Scheme (PBS). As of mid-2025, Wegovy is not listed on the PBS for weight management purposes, meaning patients must pay full private costs. Ozempic, a lower-dose semaglutide product, has PBS coverage for type 2 diabetes but not for obesity treatment. Mounjaro similarly remains largely outside PBS subsidy for weight-related prescriptions. Eligibility for these treatments typically requires a prescription from a registered healthcare provider, often after assessment of BMI, comorbidities, and previous weight management history. Many patients access these medications through specialist obesity clinics, endocrinologists, or GP-led healthcare programs.
Private Cost of Wegovy in Australia
Without PBS support, Wegovy is a significant out-of-pocket expense. Monthly costs in Australia typically range from approximately $300 to $500 AUD depending on the dose and the pharmacy or clinic dispensing it. As patients titrate up to maintenance doses, costs can increase. Some private clinics bundle the cost of the injectable medication with consultation fees, monitoring, and telehealth support, which can affect overall pricing.
Private Cost of Mounjaro in Australia
Mounjaro pricing follows a similar pattern. Monthly costs for tirzepatide through private prescription in Australia are generally estimated between $350 and $550 AUD, depending on dose strength and where it is sourced. Again, higher maintenance doses tend to sit at the upper end of that range. Costs vary between pharmacies and clinic-based dispensing programs, so it is worth comparing providers before committing to treatment.
Comparing Wegovy and Mounjaro Costs
| Medication | Active Ingredient | Approx. Monthly Cost (AUD) | PBS Listed (Obesity) | Prescription Required |
|---|---|---|---|---|
| Wegovy | Semaglutide | $300 – $500 | No | Yes |
| Mounjaro | Tirzepatide | $350 – $550 | No | Yes |
| Ozempic (lower dose) | Semaglutide | $100 – $150 (PBS for diabetes) | Partial (diabetes only) | Yes |
| Saxenda | Liraglutide | $300 – $450 | No | Yes |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
Choosing a Clinic or Healthcare Provider
Accessing these injectable medications in Australia requires working through a qualified healthcare provider. Options include GP clinics, private obesity clinics, endocrinology specialists, and telehealth platforms that operate nationally. Telehealth services have expanded access to GLP-1 treatments considerably, particularly in regional areas. When comparing clinics, it is worth asking about consultation fees, ongoing monitoring costs, and whether the treatment program includes dietary or lifestyle support alongside medication. Healthcare providers will assess your suitability for treatment before issuing a prescription.
Understanding the Broader Treatment Picture
While the cost of GLP-1 injectable medications can be substantial, many healthcare professionals consider them within a broader obesity management strategy that includes nutrition, physical activity, and behavioural support. The treatment is generally intended for people with a BMI above a certain threshold, often with associated health conditions. Duration of treatment varies, and long-term use is often required to maintain results, which means ongoing costs should be factored into any decision.
For Australians considering semaglutide or tirzepatide-based treatment, understanding both the clinical pathway and the financial commitment is essential. Speaking with a qualified healthcare provider is the most reliable way to assess personal eligibility, explore current pricing, and determine which option aligns with your health goals and budget.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
